Effect of ascorbic acid intake on tissue dehydroascorbic acid in mice

Tsao, Constance S.; Leung, Ping Y.

doi:10.1016/s0271-5317(89)80162-9

Cited by 3 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Trace amounts (less than 1%) were found in organs, mainly the liver, lungs and kidneys. Tsao and Salimi (1983) investigated the fate of ascorbic acid and erythorbic acid until steady state was reached in Swiss Webster mice. The results indicated that each isomer has established equilibrium among uptake, catabolism and elimination with no interference from another.…”

Section: 11mentioning

confidence: 99%

“…The sodium ion of sodium erythorbate is expected to enter the sodium pool of the body. Although rodents seemed to have less efficient erythorbate absorption than humans, the available study in mouse indicated that gastrointestinal absorption occurs (Tsao and Salimi, 1983). Guinea pig, a species more analogous to human due to its active-carrier mediated transport, has near complete excretion within 24 h (Hornig, 1975).…”

Section: Human Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Scientific Opinion on the re‐evaluation of erythorbic acid (E 315) and sodium erythorbate (E 316) as food additives

2016

EFS2

View full text Add to dashboard Cite

The EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS) provides a scientific opinion reevaluating the safety of erythorbic acid (E 315) and sodium erythorbate (E 316) as food additives. The use of these food additives was evaluated by the Scientific Committee on Food (SCF) that established an acceptable daily intake (ADI) of 6 mg/kg body weight (bw)/day. Intestinal absorption of erythorbate was reported from a mice study and near complete excretion within 24 h from a guinea pig study. The Panel noted that the acute toxicity of erythorbic acid or sodium erythorbate is low, there was no indication of adverse effects from the available subchronic toxicity studies, there is no concern with respect to their genotoxicity neither to respect to carcinogenicity. The Panel identified a no observed adverse effect level (NOAEL) of 650 mg/kg bw/day based on a decrease in body weight from a carcinogenicity study. No maternal and developmental effects were observed from a prenatal developmental toxicity study with sodium erythorbate. The Panel recognised the limitation of the overall toxicological database (no reproductive and chronic toxicity studies), but did not consider necessary to increase the usual uncertainty factor of 100 in deriving an ADI. Therefore, the Panel concluded that there is no reason to revise the current ADI of 6 mg/kg bw/day. Combined dietary exposure to erythorbic acid and sodium erythorbate from their use as food additives was calculated. Considering that the ADI is not exceeded by any population group, the Panel also concluded that the use of erythorbic acid (E 315) and sodium erythorbate (E 316) 1962, 1974 and 1990, and in its latest evaluation allocated an acceptable daily intake (ADI) 'not specified'. The Scientific Committee on Food (SCF) evaluated erythorbic acid and sodium erythorbate in 1987, 1990 and 1997, and an ADI of 6 mg/kg bw/day was confirmed in the latest evaluation.The absorption, distribution, metabolism and excretion (ADME) of erythorbates was considered to be similar to that of ascorbic acid. The sodium ion of sodium erythorbate is expected to enter the sodium pool of the body. Although rodents seemed to have less efficient erythorbate absorption than humans, the available study in mouse indicated that gastrointestinal absorption occurs (Tsao and Salimi, 1983). Guinea pig, a species more analogous to human due to its active-carrier mediated transport, has near complete excretion within 24 h.The Panel noted that erythorbic acid can increase iron bioavailability, which may represent a concern for individuals with iron deposition disorders.The Panel noted that the acute toxicity of erythorbic acid or sodium erythorbate is low. The Panel also noted that in the available subchronic toxicity studies there were some limitations mainly concerning reporting, however, none of them reported any adverse effects and there was no histopathological indication of any adverse effects even after 36 weeks of exposure up to 900 mg/kg body weight (bw)/day.The Panel consider...

show abstract

Section: 11mentioning

confidence: 99%

Section: Human Studiesmentioning

confidence: 99%

Scientific Opinion on the re‐evaluation of erythorbic acid (E 315) and sodium erythorbate (E 316) as food additives

2016

EFS2

View full text Add to dashboard Cite

show abstract

Carbon tetrachloride-induced alterations in hepatic glutathione and ascorbic acid contents in mice fed a diet containing ascorbate esters

Nakagawa

1993

Arch Toxicol

View full text Add to dashboard Cite

The effects of L-ascorbyl stearate and L-ascorbyl palmitate on carbon tetrachloride-induced alterations in glutathione and ascorbic acid content in mouse livers were investigated. Powdered food containing 1% ascorbate ester was given to mice for 3 days before and 1 day after a single injection of CCl4 (0.1 ml/kg, i.p.). Biochemical parameters were determined 1 day after the CCl4 administration. The ascorbate esters markedly attenuated CCl4-induced alterations such as reductions in ascorbate content and hepatic glutathione S-transferase (GST) activity, and increases in glutathione and calcium content and serum GST activity. The CCl4-induced rise in thiobarbituric acid-reactive substances, an index of lipid peroxidation, was not affected by ascorbate feeding. These findings suggest that exogenous ascorbate, in addition to endogenous glutathione, is available to maintain the intracellular milieu in a reduced state, and that this system operates more effectively in aqueous compartments than in membrane lipid bilayers.

show abstract

Inhibiting effect of ascorbic acid on the growth of human mammary tumor xenografts

Tsao

1991

The American Journal of Clinical Nutrition

View full text Add to dashboard Cite

The effect of ascorbic acid on the growth of a human mammary tumor in mice has been investigated using the 6-d subrenal capsule assay method. The results indicated that ascorbic acid administered in the drinking water significantly inhibited the growth of the tumor fragments implanted beneath the renal capsule of mice. Administration of a mixture of ascorbic acid and cupric sulfate orally or intraperitoneally significantly inhibited tumor growth in these mice, whereas neither alone was effective. These results support the hypothesis that certain oxidation or degradation products of ascorbic acid were active antineoplastic agents for the human mammary tumor studied. The activity of D-isoascorbic acid, an isomer of ascorbic acid, was similar to that of ascorbic acid. This suggests that the antitumor activity of ascorbic acid was not due to the metabolism of ascorbic acid as a vitamin, but due to its chemical properties.

show abstract

Effect of ascorbic acid intake on tissue dehydroascorbic acid in mice

Cited by 3 publications

References 28 publications

Scientific Opinion on the re‐evaluation of erythorbic acid (E 315) and sodium erythorbate (E 316) as food additives

Scientific Opinion on the re‐evaluation of erythorbic acid (E 315) and sodium erythorbate (E 316) as food additives

Carbon tetrachloride-induced alterations in hepatic glutathione and ascorbic acid contents in mice fed a diet containing ascorbate esters

Inhibiting effect of ascorbic acid on the growth of human mammary tumor xenografts

Contact Info

Product

Resources

About